By Stephen Nakrosis
Shares of Axsome Therapeutics rose post-market after the company received approval for Symbravo from the Food and Drug Administration.
Symbravo, for the acute treatment of migraine with or without aura in adult patients, showed superior efficacy across a broad range of severity, Axsome said Thursday. A single oral dose gave patients rapid relief and allowed a return to normal functioning within two hours, Axsome said.
Axsome's stock was up less than 1% to $109.00 following the market close after touching an all-time high of $111.51 during the regular session. Shares closed the market session up 3.5% at $108.85.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 30, 2025 18:59 ET (23:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.